Outcomes in patients with anthracycline‐induced cardiomyopathy undergoing left ventricular assist devices implantation

Improved cancer survivorship has led to a higher number of anthracycline‐induced cardiomyopathy patients with end‐stage heart failure. We hypothesize that outcomes following continuous‐flow LVAD (CF‐LVAD) implantation in those with anthracycline‐induced cardiomyopathy are comparable with other aetiologies of cardiomyopathy.

[1]  Arjun K. Ghosh,et al.  Cardio-oncology for the general physician: 'old' and 'new' cardiovascular toxicities and how to manage them. , 2020, British journal of hospital medicine.

[2]  C. Cipolla,et al.  Cardiotoxicity of Anthracyclines , 2020, Frontiers in Cardiovascular Medicine.

[3]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[4]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[5]  N. Desai,et al.  Neurohormonal Blockade and Clinical Outcomes in Patients With Heart Failure Supported by Left Ventricular Assist Devices. , 2019, JAMA cardiology.

[6]  N. Desai,et al.  Clinical Implications of Respiratory Failure in Patients Receiving Durable Left Ventricular Assist Devices for End-Stage Heart Failure. , 2019, Circulation: Heart Failure.

[7]  H. Jneid,et al.  Health care utilization and mortality associated with heart failure‐related admissions among cancer patients , 2019, ESC heart failure.

[8]  M. Bittencourt,et al.  Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. , 2018, Journal of the American College of Cardiology.

[9]  F. Girolami,et al.  Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience , 2018, European journal of heart failure.

[10]  A. Bhimaraj,et al.  Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure , 2018, Cardio-Oncology.

[11]  T. Sio,et al.  Coronary artery bypass grafting in patients treated with thoracic radiation: a case–control study , 2018, Open Heart.

[12]  Robert L Kormos,et al.  Eighth annual INTERMACS report: Special focus on framing the impact of adverse events. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  C. Morgan,et al.  INTERMACS Analysis of Stroke During Support With Continuous-Flow Left Ventricular Assist Devices: Risk Factors and Outcomes. , 2017, JACC. Heart failure.

[14]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[15]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of cardiac failure.

[16]  Robert L Kormos,et al.  Seventh INTERMACS annual report: 15,000 patients and counting. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  Kiyotaka Fukamachi,et al.  Does pulsatility matter in the era of continuous-flow blood pumps? , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[19]  R. Starling,et al.  Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). , 2014, Journal of the American College of Cardiology.

[20]  S. Kimmel,et al.  Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support , 2014, Circulation. Heart failure.

[21]  Eugene H Blackstone,et al.  Major bleeding during HeartMate II support. , 2013, Journal of the American College of Cardiology.

[22]  T. Intragumtornchai,et al.  Protein C, protein S and von Willebrand factor levels correlate with bleeding symptoms: a population‐based study , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  Robert L Kormos,et al.  Infection after implantation of pulsatile mechanical circulatory support devices. , 2010, The Journal of thoracic and cardiovascular surgery.

[24]  F. Veglia,et al.  Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. , 2010, Journal of the American College of Cardiology.

[25]  E. Yeh,et al.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. , 2009, Journal of the American College of Cardiology.

[26]  Giovanni Martinelli,et al.  Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition , 2006, Circulation.

[27]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[28]  L. Goldman,et al.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. , 1979, The New England journal of medicine.